Form 8-K - Current report:
SEC Accession No. 0001193125-19-288338
Filing Date
2019-11-08
Accepted
2019-11-08 16:02:03
Documents
12
Period of Report
2019-11-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d826863d8k.htm   iXBRL 8-K 28405
  Complete submission text file 0001193125-19-288338.txt   147354

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA urgn-20191104.xsd EX-101.SCH 3065
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE urgn-20191104_lab.xml EX-101.LAB 17375
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE urgn-20191104_pre.xml EX-101.PRE 10950
10 EXTRACTED XBRL INSTANCE DOCUMENT d826863d8k_htm.xml XML 3232
Mailing Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007
Business Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007 972 9 770 7601
UroGen Pharma Ltd. (Filer) CIK: 0001668243 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38079 | Film No.: 191204009
SIC: 2834 Pharmaceutical Preparations